Boston Scientific Corporation, a leader in medical device innovation, has shown steady growth prospects fueled by its expanding product portfolio in the healthcare sector. The stock's fundamental ratings and analyst projections provide a positive outlook for potential investors. However, market conditions and industry-specific risks should still be carefully considered.
Boston Scientific Corporation has a solid fundamental rating overall, reflecting a balanced approach to value and growth strategies.
Category | Score | Visualization |
---|---|---|
Discounted Cash Flow (DCF) | 4 | |
Return on Equity (ROE) | 4 | |
Return on Assets (ROA) | 4 | |
Debt to Equity | 2 | |
Price to Earnings (P/E) | 1 | |
Price to Book (P/B) | 1 |
The following table displays the historical fundamental scores of Boston Scientific Corporation.
Date | Overall Score | DCF | ROE | ROA | Debt to Equity | P/E | P/B |
---|---|---|---|---|---|---|---|
2025-05-30 | 3 | 4 | 4 | 4 | 2 | 1 | 1 |
Previous | 0 | 4 | 4 | 4 | 2 | 1 | 1 |
Analyst price targets for Boston Scientific Corporation indicate a generally positive outlook, with a consensus leaning towards a buy recommendation.
High | Low | Median | Consensus |
---|---|---|---|
$130 | $100 | $117 | $117.2 |
The analyst sentiment for Boston Scientific Corporation reflects a strong buy inclination, supported by a majority of buy recommendations.
Recommendation | Count | Visualization |
---|---|---|
Strong Buy | 2 | |
Buy | 36 | |
Hold | 3 | |
Sell | 0 | |
Strong Sell | 0 |
Boston Scientific Corporation presents a compelling investment opportunity, supported by solid fundamentals and strong analyst sentiment. The company's diversified product line and robust market position enhance its growth potential. However, investors should remain vigilant about industry dynamics and macroeconomic challenges. Careful analysis and strategic decision-making will be key to maximizing returns while managing potential risks.